MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2024-25)
- Udyam number
- UDYAM-GJ-01-0153692
R.S. Surgipharm Private Limited - pharma in Ahmedabad, Gujarat, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹134.47 Cr
▲ 32% YoY
Net profit · FY 2025
₹1.06 Cr
Net margin 0.8%
EBITDA · FY 2025
₹3.1 Cr
EBITDA margin 2.3%
Authorised capital
₹50 Lakh
Registered with MCA
Paid-up capital
₹50 Lakh
Issued & subscribed
Open charges
₹17.36 Cr
Secured borrowings
Company age
13 yrs
Est. 2013
Directors on board
4
As per MCA filings
About R.S. Surgipharm Private Limited
Data last updated:
R.S. Surgipharm Private Limited is a private limited company based in Ahmedabad, Gujarat, India. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 02 April 2013 and has been in existence for over 13 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN U24230GJ2013PTC074294.
The company has an authorised share capital of ₹50 Lakh and a paid-up capital of ₹50 Lakh. It is led by directors including Daksh Shah (Whole-Time Director) and Ashish Kantilal Shah.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Ahmedabad, Gujarat.
As per the financials filed for FY 2025, the company reported a revenue of ₹134.47 Cr, a growth of 32% compared to the previous year. For the same year it recorded a net profit of ₹1.06 Cr (net margin 0.8%) and EBITDA of ₹3.1 Cr (EBITDA margin 2.3%). Revenue has grown at a compounded annual rate (CAGR) of 94% over three years and 84% over five years.
As per MCA filings, the company has open charges of ₹17.36 Cr on record.
R.S. Surgipharm Private Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-GJ-01-0153692). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website rssurgipharm.com.
Company details
CIN U24230GJ2013PTC074294
Registration Number 074294
Incorporation Date 02 April 2013
ROC Ahmedabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-GJ-01-0153692
Key People
Daksh Shah Whole-Time Director Ashish Kantilal Shah Director Dushyantbhai Shashikantbhai Zaveri Director Recognitions & Rankings of R.S. Surgipharm
Contact details
R.S. Surgipharm Private Limited's registered office is in Ahmedabad, Gujarat. Its website is rssurgipharm.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address501/502 5th Floor Serenity Square, Opp. Navrang Complex Opp. Navrang School, Ahmedabad, Gujarat, India – 380009
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of R.S. Surgipharm Private Limited, buy the company report.
Comprehensive company report
R.S. Surgipharm Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of R.S. Surgipharm is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of R.S. Surgipharm Private Limited, buy the company report.
Financials of R.S. Surgipharm Private Limited
FY 2025 filings availableR.S. Surgipharm Private Limited reported revenue of ₹134.47 Cr (up 32% YoY) for FY 2025.
Revenue · FY 2025
₹134.47 Cr ▲ 32%
Net profit · FY 2025
₹1.06 Cr margin 0.8%
EBITDA · FY 2025
₹3.1 Cr margin 2.3%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 32%
3 years · compounded
▲ 94%
5 years · compounded
▲ 84%
EBITDA CAGR growth
1 year
▲ 26%
3 years · compounded
▲ 296%
5 years · compounded
▲ 147%
Revenue has grown at a compounded annual rate (CAGR) of 84% over five years, including 32% growth in the latest year. EBITDA rose 26% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹3.1 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹1.06 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 2.3% | ||||
| Net Profit Margin | 0.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of R.S. Surgipharm Private Limited, buy the company report.
Board of directors of R.S. Surgipharm Private Limited
R.S. Surgipharm has 4 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Daksh Shah | Whole-Time Director | 14 Jun 2021 | 5 Years 4 Months | Current |
| Ashish Kantilal Shah Also directs: Sarone Pharmaceuticals Private Limited | Director | 02 Apr 2013 | 13 Years 7 Months | Current |
| Dushyantbhai Shashikantbhai Zaveri | Director | 08 Mar 2022 | 4 Years 7 Months | Current |
| Krunal Ashwinbhai Patel | Director | 08 Mar 2022 | 4 Years 7 Months | Current |
Peer comparison
R.S. Surgipharm Private Limited is compared with the 10 companies closest to it by revenue in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Sidson Pharma Distributors Private Limited | ₹139.76 Cr (FY 2025) | -13.0% | Hyderabad, Telangana, India | |||
| Aushadhiv Specialty Pharmaceuticals Private Limited | ₹139.2 Cr (FY 2025) | 56.0% | Bangalore, Karnataka, India | |||
| BLD Pharmatech (India) Private Limited | ₹137.25 Cr (FY 2025) | 23.0% | Hyderabad, Telangana, India | |||
| Surat Sales Pvt Ltd | ₹135.04 Cr (FY 2025) | 121.0% | Surat, Gujarat, India | |||
| Organon (India) Private Limited | ₹134.83 Cr (FY 2025) | 20.0% | Mumbai, Maharashtra, India | |||
| R.S. Surgipharm Private Limitedthis company | ₹134.47 Cr (FY 2025) | ₹1.06 Cr | 0.8% | 32.0% | Ahmedabad, Gujarat, India | |
| Shivanitin Agencies Private Limited | ₹132.83 Cr (FY 2025) | 50.0% | Dehradun, Uttarakhand, India | |||
| Signova Pharma Private Limited | ₹130.91 Cr (FY 2025) | 0.0% | Guwahati, Assam, India | |||
| Milton Lifecare Private Limited | ₹130.32 Cr (FY 2024) | 37.0% | Mumbai, Maharashtra, India | |||
| Oceanic Techno Chem Private Limited | ₹128.85 Cr (FY 2025) | 57.0% | Mumbai, Maharashtra, India | |||
| Vasavi Medicare Solutions Private Limited | ₹128.66 Cr (FY 2025) | 20.0% | Coimbatore, Tamil Nadu, India |
To see the full peer comparison of R.S. Surgipharm Private Limited, buy the company report.
Auditor
R.S. Surgipharm Private Limited is audited by Maulik shah & Co for the financial year 2022.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Maulik shah & Co | FY 2022 | 129132W |
Shareholding
The shareholding of R.S. Surgipharm Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of R.S. Surgipharm Private Limited, buy the company report.
Charges & borrowings
Open charges
₹17.36 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 14 Feb 2023 | 100695667 | Others | ₹16.36 Cr | Open | |
| 25 Sep 2017 | 100130764 | Others | ₹1 Cr | Open |
To see the full charge records of R.S. Surgipharm Private Limited, buy the company report.
Total charge records: 2 View all charges
Legal cases
No court or tribunal cases involving R.S. Surgipharm Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for R.S. Surgipharm Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for R.S. Surgipharm Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
R.S. Surgipharm Private Limited has 8 board changes on record since 2013: 6 appointments and 2 cessations. The latest: Dushyantbhai Shashikantbhai Zaveri was appointed as Director on 08 Mar 2022.
AGM
R.S. Surgipharm Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
R.S. Surgipharm Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Charges
A charge with Others of Rs. 1,636.23 Lakh registered on 14 Feb 2023 with Charge ID 100695667 was modified on 03 Mar 2025.
Charges
A charge with Others amounted to Rs. 1,636.23 Lakh with Charge ID 100695667 was registered on 14 Feb 2023.
Appointed
Dushyantbhai Shashikantbhai Zaveri was appointed as Director.
Ceased
Jasmina Ashish Shah ceased to be Director.
Appointed
Krunal Ashwinbhai Patel was appointed as Director.
Ceased
Rajendrabhai Jivanlal Shah ceased to be Director.
Appointed
Daksh Shah was appointed as Whole-Time Director.
Charges
A charge with Others amounted to Rs. 100.00 Lakh with Charge ID 100130764 was registered on 25 Sep 2017.
Appointed
Ashish Kantilal Shah was appointed as Director.
Appointed
Jasmina Ashish Shah was appointed as Director.
2 earlier events are in the company report.
Frequently asked questions
R.S. Surgipharm is an active private limited company based in Ahmedabad, Gujarat, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 02 April 2013 (13+ years old) and is registered under CIN U24230GJ2013PTC074294.
R.S. Surgipharm has 4 current directors:
- Daksh Shah - Whole-Time Director
- Ashish Kantilal Shah - Director
- Dushyantbhai Shashikantbhai Zaveri - Director
- Krunal Ashwinbhai Patel - Director
The latest financial statements of R.S. Surgipharm on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of R.S. Surgipharm is U24230GJ2013PTC074294. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
R.S. Surgipharm was incorporated on 02 April 2013, making it 13+ years old. It is registered with the Registrar of Companies, Ahmedabad.
The peers of R.S. Surgipharm by revenue are Sidson Pharma Distributors Private Limited, Aushadhiv Specialty Pharmaceuticals Private Limited, BLD Pharmatech (India) Private Limited, Surat Sales Pvt Ltd, Organon (India) Private Limited and 5 more, all in the Pharma industry (Pharma Retail and Distribution), with the same principal business activity (wholesale trading).
Dushyantbhai Shashikantbhai Zaveri was appointed as Director on 08 Mar 2022. Jasmina Ashish Shah ceased to be Director on 08 Mar 2022. Krunal Ashwinbhai Patel was appointed as Director on 08 Mar 2022. R.S. Surgipharm has 8 board changes on record in total.
Yes, R.S. Surgipharm is registered as a medium enterprise under Udyam registration (number: UDYAM-GJ-01-0153692).
R.S. Surgipharm can be reached through the website rssurgipharm.com. Its registered office is in Ahmedabad, Gujarat, India.
The registered office of R.S. Surgipharm is at 501502 5th Floor Serenity Square, Opp. Navrang Complex Opp. Navrang School, Ahmedabad, Gujarat, India – 380009.
R.S. Surgipharm operates in the pharma industry, in the pharmaceutical retailers and distributors segment.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages